| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
As a stable isotope-labeled metabolite, pyruvic acid-¹³C-2 sodium targets metabolic pathways; it is used as a tracer to study glycolysis, the citric acid cycle, and gluconeogenesis; it does not have a pharmacological target but serves as a metabolic probe.
|
|---|---|
| ln Vitro |
In vitro, pyruvic acid-¹³C-2 sodium is used in cell culture to trace metabolic flux through central carbon metabolism; it is incorporated into cells and metabolized to ¹³C-labeled lactate, alanine, and TCA cycle intermediates; detection is performed by NMR or mass spectrometry.
|
| ln Vivo |
In vivo, pyruvic acid-¹³C-2 sodium is administered to animals or humans as a metabolic tracer; it is rapidly metabolized and its ¹³C label is incorporated into downstream metabolites, allowing the study of metabolic pathways and flux in various tissues.
|
| Enzyme Assay |
Non-cellular assay procedure: Pyruvic acid-¹³C-2 sodium is dissolved in aqueous buffer and incubated with enzyme preparations (e.g., lactate dehydrogenase or pyruvate dehydrogenase) to study enzyme kinetics; the reaction products are analyzed by ¹³C-NMR or mass spectrometry to monitor the transfer of the ¹³C label.
|
| Cell Assay |
Cellular assays: Cells (e.g., hepatocytes, myocytes, or cancer cells) are cultured with pyruvic acid-¹³C-2 sodium in medium; cells are harvested at various time points; metabolites are extracted and analyzed by LC-MS/MS or ¹³C-NMR to determine isotopic enrichment and metabolic flux through glycolysis, the TCA cycle, and related pathways.
|
| Animal Protocol |
In vivo animal experiments: Pyruvic acid-¹³C-2 sodium is administered to rodents via intravenous or intraperitoneal injection; blood and tissue samples are collected at timed intervals; ¹³C-enrichment in metabolites such as lactate, alanine, glutamate, and citrate is measured by mass spectrometry or NMR to assess metabolic flux.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties: Pyruvic acid-¹³C-2 sodium behaves identically to unlabeled pyruvic acid; it is rapidly absorbed and distributed; it is metabolized via pyruvate dehydrogenase, lactate dehydrogenase, and alanine aminotransferase; the ¹³C label is incorporated into various metabolites.
|
| Toxicity/Toxicokinetics |
Toxicological profile: Pyruvic acid-¹³C-2 sodium is a stable isotope-labeled metabolite with low toxicity; it is generally recognized as safe for metabolic studies at tracer doses; standard laboratory safety precautions for handling chemicals should be followed.
|
| References | |
| Additional Infomation |
Other information: Pyruvic acid-¹³C-2 sodium has a molecular formula of C₂¹³CH₃NaO₃ and a molecular weight of 111.04; it is used in metabolomics and flux analysis studies; the ¹³C labeling at the C-2 position enables specific tracking of carbon atoms through metabolic pathways.
|
| Molecular Formula |
C213CH3NAO3
|
|---|---|
| Molecular Weight |
111.04
|
| Exact Mass |
111.001
|
| CAS # |
87976-71-4
|
| Related CAS # |
Pyruvic acid;127-17-3
|
| PubChem CID |
23681380
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
>300ºC(lit.)
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
7
|
| Complexity |
88.2
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)[13C](=O)[O-].[Na+]
|
| InChi Key |
DAEPDZWVDSPTHF-FJUFCODESA-M
|
| InChi Code |
InChI=1S/C3H4O3.Na/c1-2(4)3(5)6;/h1H3,(H,5,6);/q;+1/p-1/i3+1;
|
| Chemical Name |
sodium;2-oxo(113C)propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.0058 mL | 45.0288 mL | 90.0576 mL | |
| 5 mM | 1.8012 mL | 9.0058 mL | 18.0115 mL | |
| 10 mM | 0.9006 mL | 4.5029 mL | 9.0058 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
